logo
Scientists look to Indigenous history to manage flood risk in Hawkesbury-Nepean Valley

Scientists look to Indigenous history to manage flood risk in Hawkesbury-Nepean Valley

Accounts of floods recorded in Aboriginal oral history centuries ago could provide vital clues to how climate change will affect flood risk in the future.
Scientists working on a disaster adaptation plan for the Hawkesbury-Nepean Valley in Sydney's north-west are looking into the past to help predict the future.
Stephen Yeo, senior flood risk specialist at the NSW Reconstruction Authority, said records at Windsor go back to the early days of European settlement.
"On this river system, we have the longest record of floods in Australia from the early 1790s right up to the present," he said.
"That's actually pretty short in geological time."
The biggest flood recorded since European settlement was in June 1867.
But there are early colonial accounts of Aboriginal elders describing an even bigger flood that happened eight years before the arrival of the First Fleet.
"During that flood it apparently poured in torrents for seven nights and seven days," Dr Yeo said.
He said this event changed what scientists know about the magnitude and frequency of flooding in the river system.
"It suggests that the flood in 1780 was perhaps 2 or 3 metres higher than what we currently think is the record flood in 1867.
"So that's actually really valuable information from that Aboriginal storytelling."
Waterway scientist Daryl Lam is part of a team searching for traces of pre-settlement floods.
"History is telling us what has happened before really can happen again, so if we can find evidence of big floods from the past, it gives us some understanding of what we can potentially see in climate change," he said.
Samples of sediment have been collected from three locations high above the river bank.
These samples will be taken back to a laboratory and analysed to pinpoint exactly when the sediment was deposited.
Measurements taken at the site will allow researchers to calculate how high the floodwaters rose.
"Here in the Hawkesbury-Nepean, we have gauge records that go beyond a hundred years," Dr Lam said.
"If we take into account oral history, we might be able to push it out to 200 years or 500 if we are lucky.
"With paleoflood reconstruction, we will be able to work out a longer timescale."
Archaeologist Bec Chalker said evidence of Aboriginal occupation can be found in caves all along the river.
"We find tools that are hidden up on crevices in the shelters, just like we would put our tools and kitchen utensils on a shelf at home."
She said Indigenous knowledge built up over generations was proving to be a valuable resource.
"We have a lot to learn, and I think people are more open to learning now."
Climate change is adding to the flood risk with every degree of atmospheric warming increasing rainfall in the catchment by 8 per cent.
Between 2020 and 2022, the area flooded six times.
With 114,000 people now living on the flood plain, the NSW Reconstruction Authority is considering whether building levees and improving evacuation roads will help mitigate the risk.
"Climate change is here, we have to factor it into today's decision-making," Dr Yeo said.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Breakthrough for Rhythm's next-gen bowel test
Breakthrough for Rhythm's next-gen bowel test

The Australian

time5 hours ago

  • The Australian

Breakthrough for Rhythm's next-gen bowel test

ColoSTAT diagnostic performance consistent across colorectal cancer I to IV stages Performance meets clinical requirements for symptomatic patient testing use case Commercialisation steps underway as ColoSTAT kit transitioned to final production validation state Special Report: Rhythm Biosciences has announced that its second-generation ColoSTAT blood test detects colorectal cancer consistently across all stages of the disease, marking an important milestone as the company prepares for commercialisation later this year. Following completion of ColoSTAT Beta kit verification and validation announced in May, the Rhythm Biosciences (ASX:RHY) development team has received a batch of ColoSTAT kits produced by Quansys Biosciences using the final manufacturing process. As part of the validation process, blood samples from 300 patients, ranging from those without bowel cancer to those with stage I to IV of the disease, were tested to assess how well ColoSTAT works across all stages. While further studies will be completed, the results show the test is equally effective at detecting colorectal cancer at every stage, which is an important finding given its intended use for symptomatic patients who could have either early- or late-stage cancer tests often struggle to detect early-stage disease, so the fact that ColoSTAT performs well at this stage is seen as particularly important. The predictive cancer diagnostics technology company expects to finalise validation of the kits, algorithm, and instrumentation in the near term, ahead of a submission to the National Association of Testing Authorities (NATA) in Australia to include ColoSTAT in its ISO15189 laboratory test portfolio. NATA is Australia's primary accreditation body for laboratories and testing facilities. Commercial launch of ColoSTAT is planned for later in CY25, subject to NATA regulatory approval. Watch: CEO David Atkin's talks about early cancer detection. 'Establishing a clinically useful product' ColoSTAT is a simple, minimally invasive blood test designed for people unwilling or unable to undergo traditional screening methods for colorectal (bowel) cancer, the world's second leading cause of cancer deaths but highly treatable when detected early. The test identifies specific protein biomarkers in the blood that indicate the likelihood of colorectal cancer. The second-generation ColoSTAT blood test involved a redesign of the assay from a single-plex into a multiplex format with several objectives including: Simplify completion of the test for a routine laboratory Reduce turnaround times (TAT) Improve the quality and performance of the assay Reduce overall cost of goods for the assay Clinical advisor Dr Andy Feber said demonstrating performance across the full spectrum of neoplastic conditions was essential for a clinically useful product. 'Establishing ColoSTAT performance across the entire range of neoplastic conditions is an important requirement for a clinically useful product,' he said. 'I'm pleased to see this important milestone has been achieved.' This article was developed in collaboration with Rhythm Biosciences, a Stockhead advertiser at the time of publishing. This article does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.

Fears Vitamin B6 levels in energy drinks like Red Bull and Monster could contribute to rise in B6 toxicity cases
Fears Vitamin B6 levels in energy drinks like Red Bull and Monster could contribute to rise in B6 toxicity cases

ABC News

time9 hours ago

  • ABC News

Fears Vitamin B6 levels in energy drinks like Red Bull and Monster could contribute to rise in B6 toxicity cases

Concerns are mounting over an ingredient in energy drinks that has been linked to a growing number of life-altering blood toxicity cases. Vitamin B6 is considered an essential vitamin and is widely available in a balanced diet, with a recommended daily intake of just 1.3mg — 1.7mg per day for adults. But debilitating health problems can occur when a manufactured form of B6 — also known as pyridoxine hydrochloride, pyridoxamine, or pyridoxal — is consumed in excess. A 250ml can of Red Bull contains 5 milligrams of Vitamin B6, a 500ml can of Mother 4.3 milligrams per serve and a 500ml can of BSC Energy 10mg. "There's no good reason why energy drinks need to have six times the recommended daily intake of B6 in them," George Institute food policy researcher, Associate Professor Alexandra Jones told 730. "And while it's unlikely that you would exceed the upper limit by drinking energy drinks alone, there is a subset of the population that are likely to be simultaneously consuming energy drinks and other supplements which could also contain high levels of B6," she said. B6 is added to thousands of vitamin supplements and fortified food products — from magnesium and zinc to breakfast cereals and protein bars. Blood test data obtained by 7.30 from Australian pathology labs Sullivan Nicolaides has revealed more than 2,700 'probable' cases of neuropathy or other health issues attributed to B6 blood toxicity have occurred since January this year. "Typical consumption patterns mean people are getting much higher doses, not just from the individual products but multiple products," Dr Terri-Lynne South, a dietitian and GP said. Dr South is one of several health practitioners advocating for tighter regulations — as more cases of B6 toxicity emerge. "For the energy drinks containing 10mg of B6 — if they were vitamin supplements — they'd have to show a warning on the label," Dr South told 7.30. "There's only one reason to have a supplement for B6 — and that's if there is proven deficiency or risk of deficiency." The Australian and New Zealand Food Standards agency (FSANZ) set the limit for B6 in energy drinks at 10mg per day, around the time Red Bull entered the Australian market. "Formulated caffeinated beverages must carry an advisory statement that no more than a 'one-day quantity' should be consumed if they contain certain substances, including vitamin B6," a spokesperson told 7.30. Last month the country's medicines regulator, the Therapeutic Goods Administration (TGA), made several recommendations It called for vitamin supplements with more than 50mg of B6 to be taken off shelves and moved behind pharmacy counters. A TGA delegate last month wrote that FSANZ should consider the "appropriateness of the 10 mg limit for vitamin B6 in formulated caffeinated beverages, considering the risks from the use of multiple products containing Vitamin B6." The same delegate also described the benefits of synthetic B6 as 'negligible', said labelling is 'inconsistent' and 'confusing' and called on the multi-billion-dollar complementary medicines sector to initiate education campaigns. A spokesperson for FSANZ said: "If evidence emerges that consumers are regularly exceeding safe intake levels, FSANZ would consider raising a proposal to review the current permissions." FSANZ did not answer questions regarding how it monitors such evidence. Ms Jones said the agency typically prioritises cases where the adverse effects are immediate, not cumulative. "They're very focused on the immediate health risks of a product, so whether it would make you sick overnight, for example," she said. Geoff Parker, the CEO of the Australian Beverages Council issued a statement on behalf of Australia's energy drinks companies. He didn't answer 7.30's questions and instead compared his sector's products against complementary medicines. "Laws regulating energy drinks in Australia are among the most stringent in the world," he told 7.30. "Some popular multivitamin supplements contain about 25 mg of B6 — at least five times the average B6 in energy drinks sold in Australia. "The ... upper level of safe intake [is] 50 mg a day for adults. The average level of B6 in energy drinks sold in Australia is approximately 2.1mg for a 250ml serve." The regulations however don't prevent unprecedented or unlikely cases. Matthew* began taking Berocca daily last August after a colleague recommended it for an afternoon energy boost. The 56-year-old has a prominent public profile and asked 7.30 not to use his real name. "I work in a high-pressure environment ... by mid-afternoon, the energy levels start to wane ... one of my colleagues was having a Berocca — he said 'it gives you a boost', so I tried it, and it turned into a habit." What started as a daily pick-me-up soon escalated — at times, he was having two Beroccas in one drink. Then came the symptoms. "I felt a tingle — some pins and needles — in my left hand, it moved up my arm, then to my right hand, then into my legs, there were terrible burning sensations." Concerned about stroke or heart problems, he underwent tests for blood cancer and multiple sclerosis. His doctor eventually suggested a neurologist. "I was poisoning myself while [I was] trying to work out how I've poisoned myself." Still, he continued taking Berocca but concedes he was likely taking too much of the product. After months of suffering came the call from his GP. "He said 'you have to stop taking vitamin supplements'… I said, 'what are you talking about? I've never taken vitamins' And he said 'it's Vitamin B6'." Tests revealed Matthew had nearly three times the toxic level of B6 in his bloodstream. He stopped taking Berocca immediately. And while his symptoms improved within weeks, some burning sensations remain. "I haven't had any peripheral neuropathy for a month," he said. The mental toll though has been severe. "I am so careful about the food that I put in my mouth, the restrictions I have on drinking, the fact I exercise religiously. "I've never had serious mental issues — I'm a glass-half-full person — I don't think I've got a propensity towards depression or anything like that. "But I certainly was depressed about this — this has rocked my world, mentally." There are no warnings on Berocca packaging. Instead, it claims to improve physical energy "when consumed daily for 28 days." Berocca's parent company, pharmaceutical giant Bayer, said it is "committed to consumer safety and regulatory compliance". "All our over-the-counter products ... comply fully with TGA labelling requirements, including ingredient disclosure, dosage, and safety warnings. We will continue to abide by TGA rules and requirements." In 2020 Monique's blood became toxic after consuming protein shakes and multivitamins, she never realised the combined B6 levels were extreme. "It took about a year to be diagnosed," the 35-year-old told 7.30. "The worst state that I was in was being bed-bound for about six months, once the vestibular migraine started and I lost my balance completely. Monique believes during her recovery her symptoms were exacerbated when unwittingly consuming small amounts of B6 in a fortified drink. "I was doing really well, I was exercising again, and carefully checking everything I was eating, but after nine months of improvement I became complacent — I didn't think to check the back of the label," she said. Monique could not provide evidence concluding the fortified drink was a causal factor. Dr South believes much of the marketing around B6 is misleading. "Most of these products, promoting B-vitamins, are marketed as 'energy-giving', and that comes from the understanding that a lot of these vitamins are co-factors of generating energy in cells," she told 7.30. "We're starting to see it in multivitamin minerals from the chemist, but we need better regulations in these higher food products, especially energy drinks. "This increases the impetus for regulators like Food Standards Australian New Zealand the Therapeutic Goods Administration to coordinate together, because it's about the cumulative risks of this amount of B6 being in our food supply. Watch 7.30, Mondays to Thursdays 7:30pm on ABC iview and ABC TV Do you know more about this story? Get in touch with 7.30 here.

Health Kick Podcast: Imagion Biosystems
Health Kick Podcast: Imagion Biosystems

The Australian

time14 hours ago

  • The Australian

Health Kick Podcast: Imagion Biosystems

Stockhead's health and biotech expert Tim Boreham is back in the studio for another instalment of the Health Kick Podcast. In this episode, Tim speaks with Imagion Biosystems (ASX:IBX) chairman Robert Proulx and company advisor Dr Leonardo Kayat Bittencourt. Did you know that X-ray technology was invented more than a century ago? You can thank German scientist Wilhelm Conrad Röntgen for that. Since then, diagnostic technology in the healthcare sector has made leaps and bounds, and one of the companies at the forefront is Imagion Biosystems. Tune in to hear how IBX is accelerating early detection of cancer, how their MagSense Technology works, and more. This podcast was developed in collaboration with Imagion Biosystems, a Stockhead advertiser at the time of publishing. The interviews and discussions in this podcast are opinions only and not financial or investment advice. Listeners should obtain independent advice based on their own circumstances before making any financial decisions.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store